Net loss for Q2 widened compared to prior year quarter
Company continues clinical trials and business development for pipeline products
Result drivers
Royalty revenue - Q2 royalty revenue from TLANDO increased to $190,000 from $123,000 in the prior-year period
No license revenue - No license revenue recognized in Q2 2026, compared with $500,000 in Q2 2025
R&D spending - Research and development expenses remained high, driven by costs related to the LPCN 1154 Phase 3 study and increased personnel expense
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
LPCN•
